Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MAXXON, INC (MXON.Nasdaq BB) Disposable syringe technology -- Ignore unavailable to you. Want to Upgrade?

To: bcjt who wrote (77)	5/15/1999 8:38:00 PM
From: Joe Lyddon	Respond to of 105

I wouldn't be a bit surprised! Pump... Dump... refill... Pump... Dump... refill... etc. Just a bunch of MM & insider manipulations... They don't give a da.n about the shareholders or the Company. I will believe differently Only when I See it... Not before. I really suspect that they've run into a major design flaw that is causing more of a problem than they expected. If not, why did they have to hire a Dr. to oversee production? What production? Further debugging would be more like it! If they made it public, the stock would fall like a rock... (which is a good reason for being quiet I guess). I also think that it's possible that they have to Pump & Sell in order to get funding for the ongoing debugging process. No News is Bad News... I will wait... Good luck!

To: bcjt who wrote (77)	5/16/1999 12:53:00 AM
From: campe	Read Replies (1) \| Respond to of 105

bcjt, good insights on M-P. All these constant delays will either give REAL medical companies a chance to catch up OR reveal nothing exists. IMO, buying a PR firm to hype your product means your product isn't there to hype itself. I think all should read the thread header once again and compare it to where MXON is today. Almost two years ago (May 28th) MXON had Shares outstanding: 8,353,000, Float: 475,000, and Share price: 5.25 - 5.50. Two years ago, this company signed a letter of intent to acquire an exclusive worldwide license to manufacture and market a patented disposable syringe with automatic needle retraction. Two years later, are they any closer?